RTQ1.F AVACTA GROUP PLC LS-10
- Market cap
- EUR 322M
- P/E
- -
- P/B
- 61.22x
- ROE
- -1,559.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is RTQ1.F undervalued?
Graham numberThe Graham number of AVACTA GROUP PLC LS-10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AVACTA GROUP PLC LS-10 fundamental analysis
No fundamental analysis for AVACTA GROUP PLC LS-10 yet.
AVACTA GROUP PLC LS-10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AVACTA GROUP PLC LS-10
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the ex…
Full company profileAVACTA GROUP PLC LS-10 financial statements
AVACTA GROUP PLC LS-10 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.94M | 9.65M | 2.85M | 113K | 113K |
| Gross Profit | 2.02M | 7.24M | 2.84M | 113K | 113K |
| Operating Income | -29.1M | -27.8M | -22.0M | -31.8M | -29.4M |
| EBITDA | - | -36.0M | -15.4M | -17.6M | -27.8M |
| Net Income | -26.3M | -36.6M | -33.3M | -52.8M | -38.6M |
| EPS | -0.10 | -0.14 | -0.12 | -0.14 | -0.09 |
| Balance Sheet | |||||
| Total Assets | 47.0M | 92.9M | 73.2M | 48.3M | 29.4M |
| Total Liabilities | 5.78M | 71.9M | 56.3M | 39.0M | 26.9M |
| Shareholders' Equity | 41.2M | 21.0M | 16.9M | 9.28M | 2.48M |
| Cash & Short-term Investments | 26.2M | 41.8M | 16.6M | 12.9M | 16.9M |
| Cash Flow | |||||
| Operating Cash Flow | -20.5M | -16.4M | -14.9M | -23.6M | -26.8M |
| Capital Expenditure | 1.31M | 759K | 205K | 339K | 53.0K |
| Free Cash Flow | -21.8M | -17.2M | -15.1M | -23.9M | -26.8M |
| Ratios | |||||
| ROE | -63.8% | -174.5% | -196.7% | -569.3% | -1,559.5% |
| ROA | -56.0% | -39.4% | -45.4% | -109.5% | -131.3% |
| Net Profit Margin | -894.8% | -379.5% | -1,166.5% | -46,761.9% | -34,169.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AVACTA GROUP PLC LS-10 dividends
AVACTA GROUP PLC LS-10 has not paid dividends in the last 5 fiscal years.
Who owns AVACTA GROUP PLC LS-10
- Insiders 3.16%
- Institutions 3.11%
- Public & others 93.72%
- Shares outstanding 438M
- Free float 441M
AVACTA GROUP PLC LS-10 company profile
- Company name
- AVACTA GROUP PLC LS-10
- Ticker
- RTQ1.F
- ISIN
- GB00BYYW9G87
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 81
- Fiscal year end
- December
- Address
- Scale Space White City Imperial College Campus, London, United Kingdom, W12 7RZ
- Phone
- 44 203 9110353
- Website
- avacta.com
About AVACTA GROUP PLC LS-10
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
AVACTA GROUP PLC LS-10 management
10- Dr. Christina Marie Coughlin B.S., M.D., Ph.D.CEO & Executive Director · born 1970
- Mr. Brian M. HahnCFO & Company Secretary · born 1974
- Ms. Karen HarrisonChief Operating Officer
- Mr. Francis WilsonChief Scientific Officer
- Ms. Emma WrightGroup In-House Counsel
- Mr. Michael VinegradGroup Communications Director
- Mr. R. Craig Slater FCAChief Operating Officer of Diagnostics · born 1964
- Mr. David WilsonChief Commercial Officer of Diagnostics
- Ms. Anne McGurkJoint Managing Director of Launch Diagnostics
- Mr. Sebastien GoenenChief Operating Officer of Coris BioConcept